The manuscript was published on February 19, 2026 in Molecular Imaging and Biology, describing a template‑driven RIG‑I agonist strategy that uses overexpressed microRNAs as assembly templates to activate innate immune signaling specifically within cancer cells.
The study, conducted in collaboration with Michigan State University and led by Dr. Anna Moore, shows that the TTX nanoparticle system can selectively engage RIG‑I in tumor cells while minimizing systemic toxicity. The authors report the first in‑vivo evidence that the platform delivers the immunostimulatory agent to metastatic sites and triggers an anti‑tumor immune response.
The publication supports TransCode’s broader strategy of combining its proprietary TTX delivery technology with novel immuno‑oncology agents. The TTX platform is already being evaluated in clinical trials, and the new data suggest that the RIG‑I agonist approach could broaden the company’s pipeline beyond its lead candidate, TTX‑MC138, which targets metastatic tumors overexpressing microRNA‑10b.
"Our findings demonstrate a novel approach to precisely engage innate immune pathways directly within tumor cells, while minimizing systemic toxicity. We believe that combining tumor‑specific RNA templating with our TTX nanoparticle delivery platform brings RIG‑I‑based immunotherapy closer to clinical relevance," said Zdravka Medarova, Ph.D., CSO of TransCode.
The study’s implications extend beyond the immediate scientific advance. By proving that the TTX platform can deliver a RIG‑I agonist to metastatic lesions with tumor‑specific activation, TransCode strengthens its position in the competitive RNA‑based immunotherapy space and lays groundwork for future clinical development of a new class of RNA‑based immunotherapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.